These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9302194)

  • 1. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands.
    Herremans MM; van Loon AM; Reimerink JH; Rümke HC; van der Avoort HG; Kimman TG; Koopmans MP
    Clin Diagn Lab Immunol; 1997 Sep; 4(5):499-503. PubMed ID: 9302194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
    Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
    J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin a as a serological marker for the (silent) circulation of poliovirus in an inactivated poliovirus-vaccinated population.
    Herremans T; Kimman TG; Conyn-Van Spaendonck MA; Buisman A; de Melker H; Abbink F; Bijkerk P; Koopmans MP
    Clin Infect Dis; 2002 Apr; 34(8):1067-75. PubMed ID: 11914995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.
    Dey A; Molodecky NA; Verma H; Sharma P; Yang JS; Saletti G; Ahmad M; Bahl SK; Wierzba TF; Nandy RK; Deshpande JM; Sutter RW; Czerkinsky C
    PLoS One; 2016; 11(1):e0146010. PubMed ID: 26730586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.
    John J; Giri S; Karthikeyan AS; Iturriza-Gomara M; Muliyil J; Abraham A; Grassly NC; Kang G
    Lancet; 2014 Oct; 384(9953):1505-12. PubMed ID: 25018120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test.
    Herremans MM; Reimerink JH; Ras A; Van Der Avoort HG; Kimman TG; Van Loon AM; Conyn-Van Spaendonck MA; Koopmans MP
    Clin Diagn Lab Immunol; 1997 Nov; 4(6):659-64. PubMed ID: 9384285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
    Hotta C; Ogawa T; Shirasawa H
    Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
    Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
    Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
    Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
    Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.
    Eggers M; Terletskaia-Ladwig E; Rabenau HF; Doerr HW; Diedrich S; Enders G; Enders M
    BMC Infect Dis; 2010 Dec; 10():347. PubMed ID: 21143885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunoprophylaxis of poliomyelitis in Ukraine with the use of inactivated vaccine].
    Frolov AF; Sel'nikova OP; Zadorozhnaia VI; Moiseeva AV; Demchishina IV; Bondarenko VI; Zubkova NL; Doan SI; Buraia TA
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (1):49-53. PubMed ID: 15773400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
    Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
    Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine.
    Hendry AJ; Beard FH; Dey A; Quinn H; Hueston L; Dwyer DE; McIntyre PB
    Vaccine; 2020 Mar; 38(11):2572-2577. PubMed ID: 32037225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan.
    Satoh H; Tanaka-Taya K; Shimizu H; Goto A; Tanaka S; Nakano T; Hotta C; Okazaki T; Itamochi M; Ito M; Okamoto-Nakagawa R; Yamashita Y; Arai S; Okuno H; Morino S; Oishi K
    Vaccine; 2019 Mar; 37(14):1964-1971. PubMed ID: 30827736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of Poliomyelitis Antibodies Among Children Aged 1 to 4 Years Old and Factors Associated With Poliovirus Susceptibility; Mexican Health and Nutrition Survey, 2012.
    Díaz-Quiñónez JA; Díaz-Ortega JL; Cruz-Hervert P; Ferreira-Guerrero E; Delgado-Sánchez G; Ferreyra-Reyes L; López-Martínez I; Torres-Longoria B; Aparicio-Antonio R; Montero-Campos R; Mongua-Rodríguez N; Garcia-Garcia L
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S110-S114. PubMed ID: 30376082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman.
    Sutter RW; Suleiman AJ; Malankar PG; Mehta FR; Medany MA; Arif MA; Linkins RW; Pallansch MA; El-Bualy MS; Robertson SE
    J Infect Dis; 1997 Feb; 175 Suppl 1():S235-40. PubMed ID: 9203722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination.
    Carlsson B; Zaman S; Mellander L; Jalil F; Hanson LA
    J Infect Dis; 1985 Dec; 152(6):1238-44. PubMed ID: 2999260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.